The Parkinson’s Research Laboratory (PRL) at the University of Florida is working to pioneer novel strategies for the prevention, early detection, and improved treatment of Parkinson’s disease and related movement and memory disorders. The program is under the direction of Dr. Matt Farrer, an internationally recognized Parkinson’s disease researcher, neurogeneticist and neuroscientist with over 30 years’ experience in neurologic disease and related neurodegenerative disorders. Dr. Farrer currently holds the Lauren & Lee Fixel Chair of Parkinson’s disease research.
Dr. Matt Farrer, is critically acclaimed for his work in the genetics and neuroscience of Parkinson’s disease. His inspiration to apply genetic analysis to complex neurologic disorders came from early work as a care assistant of patients
Learn more about our residents, post doctoral students, graduate students and the staff who work in our laboratory.
The Center for Translational Research in Neurodegenerative Disease (CTRND) is a state of the art, multi-disciplinary research center focused on the discovery, development and evaluation of future treatments and diagnostics for degenerative central nervous system conditions including Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration, Parkinson’s disease, and Stroke. Their dedicated faculty and team members are conducting world-class translational research in neurodegenerative disease with a focus on translating basic discoveries into practical clinical advances that benefit those who suffer from these devastating disorders. The CTRND was started in 2010 and is a center within the UF College of Medicine, it occupies the 4th floor of the newly built Biomedical Sciences Building (insert link to the CTRND here) and maintains an open laboratory design to facilitate collaborative research.
The Norman Fixel Institute for Neurological Diseases is home to scientists and clinicians at UF Health who are working on neurological disorders that afflict millions of people across the globe. These conditions include Parkinson’s, dystonia and other movement disorders, Alzheimer’s disease and dementias, concussion, traumatic brain injury, and neuromuscular disorders like amyotrophic lateral sclerosis, also known as ALS, or Lou Gehrig’s disease. The Institute is a cornerstone of the university’s aspiration to help create history’s healthiest generation through precision health, the elimination of health disparities and the advancement of therapies related to the brain and neuromuscular and mental health. UF Health physicians and researchers conduct leading-edge treatments, such as deep brain stimulation and gene therapy that are transforming patient care. Under the umbrella of the Fixel Institute, they seek to revolutionize discoveries in Parkinson’s and other neurological diseases that will lead to new therapies and improve the quality of life for patients and forever change how these conditions are treated.
The MBI is a nexus for neuroscience at the University of Florida. Across the UF campus, more than 300 faculty members work in multidisciplinary teams to better understand how the brain works and how various diseases alter brain function. Ultimately these researchers and physician-scientists hope to help broaden the understanding of many neurological and psychiatric disorders and change them from untreatable to treatable, incurable to curable and inevitable to preventable. The MBI building houses the four “neuro” departments of the UF College of Medicine: neurology, neurosurgery, neuroscience and psychiatry. All four of these departments have major investments and research in the neurosciences and neuromedicine. The MBI supports affiliated departments, centers and numerous neuroscience research programs on the UF campus-one of few campuses in the United States that boasts all six health professional schools: medicine, dentistry, nursing, veterinary medicine, public health and pharmacy. The Parkinson’s Research Laboratory (PRL) is currently located in MBI’s main building and will move into a new dedicated space on the 1st floor in July, 2020.